Deficiency in the nuclear-encoded mitochondrial protein frataxin causes Friedreich ataxia (FRDA), a progressive neurodegenerative disorder associating spinocerebellar ataxia and cardiomyopathy. Although the exact function of frataxin is still a matter of debate, it is widely accepted that frataxin is a mitochondrial iron chaperone involved in iron -sulfur cluster and heme biosynthesis. Frataxin is synthesized as a precursor polypeptide, directed to the mitochondrial matrix where it is proteolytically cleaved by the mitochondrial processing peptidase to the mature form via a processing intermediate. The mature form was initially reported to be encoded by amino acids 56 -210 (m 56 -FXN). However, two independent reports have challenged these studies describing two different forms encoded by amino acids 78 -210 (m 78 -FXN) and 81 -210 (m 81 -FXN). Here, we provide evidence that mature human frataxin corresponds to m 81 -FXN, and can rescue the lethal phenotype of fibroblasts completely deleted for frataxin. Furthermore, our data demonstrate that the migration profile of frataxin depends on the experimental conditions, a behavior which most likely contributed to the confusion concerning the endogenous mature frataxin. Interestingly, we show that m 56 -FXN and m 78 -FXN can be generated when the normal maturation process of frataxin is impaired, although the physiological relevance is not clear. Furthermore, we determine that the d-FXN form, previously reported to be a degradation product, corresponds to m 78 -FXN. Finally, we demonstrate that all frataxin isoforms are generated and localized within the mitochondria. The clear identification of the N-terminus of mature FXN is an important step for designing therapeutic approaches for FRDA based on frataxin replacement.
INTRODUCTION
Friedreich ataxia (FRDA), an autosomal recessive neurodegenerative disease characterized by gait and limb ataxia, loss of proprioception, hypertrophic cardiomyopathy and increased incidence of diabetes, is due to deficiency of the mitochondrial protein frataxin (FXN) (1) . The common disease-causing mutation is a (GAA) n expansion within the first intron of the FXN gene (2) . Two non-exclusive hypotheses provide the mechanism by which this (GAA) n expansion leads to a strongly reduced expression of frataxin: the formation of a triple helix which interferes with transcriptional elongation (3) or epigenetic changes leading to heterochromatin formation thereby impairing gene transcription (4) . Frataxin deficiency in FRDA patients, mouse and yeast models is associated with deficiency in iron-sulfur cluster (Fe -S) enzyme activities (5 -8) , mitochondrial iron deposits (7, 9, 10) , reduced oxidative phosphorylation (11) and impaired antioxidant defense (12) . While frataxin seems likely to serve diverse cellular roles, several of these functions appear to involve iron delivery (13, 14) . Although the extent of the primary functions of frataxin is still a matter of debate, frataxin is clearly involved in mitochondrial iron homeostasis with a direct binding of frataxin to iron ions (Fe 2þ or Fe 3þ ) in a micromolar range (15 -18) . While relatively weak by physiological standards, the interaction of frataxin with its partners, such as the Fe-S cluster scaffold protein IscU is iron-dependent (19) (20) (21) . The current commonly accepted hypothesis confers a role for frataxin as an iron-chaperone involved in Fe-S biogenesis and heme biosynthesis (13, (19) (20) (21) (22) . However, its functions as an iron storage molecule (23) , an antioxidant (24, 25) or a tumor suppressor (26, 27) protein is more controversial.
There is a high degree of structural homology in frataxin proteins, from bacteria to humans, with a compact globular structure maintained by a hydrophobic network and composed of two a-helices and seven b-sheets (28, 29) . An anionic surface defined by a dozen acidic residues lies on a surface localized on the first a-helix and the b1-sheet that is solvent-exposed. This region has been demonstrated in biochemical and structural studies in yeast, bacteria and human frataxins to be crucial for its function and to be implicated in the iron binding of frataxin as well as in the ferrochelatase binding and ferroxidase activity (13, 16, 17, 20, 30, 31) .
The nuclear-encoded human frataxin protein is synthesized as a 210 amino acid precursor (23 kDa) with a N-terminal mitochondrial-targeting sequence ( Fig. 1 ) previously shown to be removed by an unusual two-step maturation process by the mitochondrial processing peptidase (MPP) (32) . The b-subunit of MPP was shown to directly interact with the frataxin precursor by yeast two-hybrid and GST pull-down experiments (33) . In vitro processing assays using recombinant MPP demonstrated an initial cleavage generating the intermediate form (i-FXN; 19 kDa) between Gly41 and Leu42 for the human protein followed by a second cleavage giving the mature form (33, 34) . The second site of maturation that gives rise to the mature form of frataxin is controversial. Initial in vitro studies reported by Cavadini et al. (34) identified the second cleavage site by radiosequencing between Ala55 and Ser56, leading to the formation of a 56-210 frataxin (m 56 -FXN; 17 kDa). However, Condo et al. (35) have recently demonstrated, by Edman degradation analysis, that immunopurified mature frataxin overexpressed in HEK-293 cells begins at Ser81 (m 81 -FXN; 14.2 kDa). Furthermore, they suggest that mature m 81 -FXN has the ability to restore the aconitase deficit in a FRDA primary fibroblast cell line. In contrast, Yoon et al. (36) have recently demonstrated an iron-mediated cleavage of frataxin in vitro leading to an activated mature 14 kDa frataxin identified by mass spectrometry to begin at amino acid 78 (m 78 -FXN; 14.5 kDa). The authors propose a structural gating role for the N-terminal residues of m 56 -FXN, which would serve to inhibit the iron-promoted binding of m 78 -FXN to the Fe -S cluster assembly scaffold partner protein, IscU (36) . Interestingly, both the m 78 -FXN and the m 81 -FXN forms have been reported not only in recombinant human frataxin purification, but also in human heart extracts as degradation products (d-FXN) (15, 20, 29, 34) . Finally, bioinformatic analysis identifies each of the three sites (between residues 41 and 42, 55 and 56 and around amino acid 81) as putative MPP cleavage sites.
We have previously seen that endogenous frataxin migrates with an apparent mobility of ,15 kDa on a 16% SDSTricine -PAGE. Other groups have reported a migration on standard SDS -Glycine -PAGE around [15] [16] [17] . This abnormal mobility on SDS -PAGE for yeast, human and murine frataxin is attributed to the acidic nature of the protein (31, 37) . It is interesting to note that endogenous human frataxin was found by different groups to co-migrate with markers corresponding to either FXN 56 -210 or FXN 81 -210 , further reinforcing the confusion as to the size of mature frataxin. In the present article, we demonstrate that the major endogenous form of mature frataxin results from a cleavage between Lys80 and Ser81, thus confirming the site described by Testi and colleagues. Besides, we provide additional evidence that m 56 -FXN is not found in normal physiological conditions and that the reported degraded form of frataxin (d-FXN) corresponds to m 78 -FXN. Finally, we show that the complete maturation process of frataxin is exclusively localized within the mitochondria.
RESULTS

Neither FXN
56 -210 nor FXN 79 -210 correspond to endogenous human mature frataxin
In a first attempt to identify the potential final maturation site of endogenous FXN, we compared the migration profile under different conditions (see Materials and Methods) of two Nterminal truncated frataxins corresponding to two potential reported mature frataxin and FXN 79 -210 ) to wildtype (WT) human frataxin overexpressed in vivo (FXN 1 -210 ) and endogenous frataxin (m-FXN) (Fig. 2) . Endogenous m-FXN from HeLa cells, fibroblasts and skeletal muscle tissue migrates between 14 and 15 kDa under all conditions (Fig. 2) . Interestingly, neither potential mature forms of frataxin (FXN 56 -210 and FXN 79 -210 ) co-migrate with endogenous m-FXN (Fig. 2) . This is particularly clear in a 14% acrylamide SDS-Glycine -PAGE in which m-FXN migrates in between the two markers (Fig. 2) . Detection of peptides close to the N-and C-termini of the truncated constructs FXN 56 -210 and FXN 79 -210 by MALDI-Peptide mass fingerprinting (PMF) shows that these recombinant proteins were not degraded after expression in cells (data not shown). Furthermore, this difference in migration is not a consequence of overexpressing a recombinant protein, as a WT construct (1-210) leads to a mature frataxin that co-migrates with endogenous m-FXN. Interestingly, the relative migration of FXN 56 -210 , FXN 79 -210 and endogenous m-FXN is dependent on the SDS-PAGE conditions (acrylamide concentration). FXN) are represented. The residues mutated in the different maturation experiments are bolded; the residues mutated for the migration profile (Fig. 5 ) are underlined. The conserved globular domain which starts at amino acid 90 is indicated by the grey area. Note that the scheme is not drawn to scale.
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Human Molecular Genetics, 2008, Vol. 17, No. 22 Indeed, at the lowest tested concentration (12%), endogenous frataxin migrates very close to FXN 56 -210 while at higher percentage of acrylamide (15%) or in SDS -Tricine (16%), endogenous frataxin co-migrates with the second marker FXN 79 -210 (Fig. 2) . This unusual behavior of frataxin may explain the contradictory reports on the identification of mature frataxin based on co-migration with different frataxin constructs (34, 35) . To determine whether endogenous mouse frataxin presents a similar profile, extracts from C2C12 myoblast cells and heart muscle tissue were compared with the two corresponding predicted forms of mature mouse frataxin (Fxn 54 -207 and Fxn 76 -207 ). Similarly to human frataxin, the endogenous murine frataxin migrated between both size markers in a 14% acrylamide gel (Supplementary Material, Fig. S1 ). Together, these results suggest that the endogenous mature form of frataxin is different from the previously described m 56 -FXN as well as m 79 -FXN.
Mature frataxin corresponds to m 81 -FXN
To identify the N-terminus of the mature form, frataxin was immunopurified from COS-1 cells overexpressing the recombinant FXN 1 -210 . Overexpression of a recombinant precursor of FXN 1 -210 56 -210 is not due to C-terminal degradation. While trypsin digestion was not appropriate to detect the N-terminal peptide of the m-FXN because of the presence of arginine and lysine residues near the predicted maturation site, Asp-N digestion (preferential cleavage: N-terminal of aspartate) uncovered a specific peak (m/z ¼ 925 498) in the mass spectrum of the mature form (Fig. 3) . This diagnostic peak, that was absent from both the precursor and the intermediate mass spectra, matches the 81-90 peptide (sequence ¼ SGTLGHPGSL/D), indicating that mature frataxin begins at the Ser81. Subsequent LC/MS/MS analysis unambiguously demonstrated that the m/z ¼ 925 498 peak corresponds to the predicted sequence of the human frataxin 81-90 peptide (data not shown). Our results thus confirm that mature frataxin corresponds to the m 81 -FXN form, as previously reported (35) .
Mature frataxin displays an unusual migration profile on SDS-PAGE
The identification of the starting residue of mature frataxin at residue 81 was surprising, since endogenous frataxin migrates higher than the theoretical molecular weight of 81 -210 also co-migrated with endogenous m-FXN (data not shown), further indicating that the abnormal migration of the mature frataxin cannot be attributed to specific post-translational modification. Moreover, in vitro dephosphorylation and N-deglycosylation assays excluded that the abnormal migration was due to these posttranslational modifications (data not shown).
Previous studies using yeast and bacterial frataxin have suggested that the abnormal migration of frataxin was due to the specific acidic nature of the protein, more specifically of its first a-helix and the b1-sheet. Mutations of some negatively charged residues (aspartates and glutamates) in the yeast frataxin significantly changed the migration on SDS -PAGE (31, 37) . We hypothesized that some of these N-terminal residues in human frataxin could confer the abnormal migration either by electrostatic change or by being implicated in a stable secondary structure of the protein. To verify this hypothesis, we performed site-directed mutagenesis of specific N-terminal residues of FXN 81 -210 (Fig. 4C ). Several mutated residues (L90, Y95, D91, E92 and D104) cause a significant modification in the migration profile. Mutants in Leu90 and Tyr95 present a slower migration than the m-FXN (Fig. 4C) . Interestingly, mutations in conserved acidic residues (D91, E92 and D104) lead to a migration consistent with the theoretical molecular weight of m 81 -FXN (14.2 kDa), but mutation in the acidic residue D91 of FXN 79 -210 did not modify its migration in gel (data not shown). These results demonstrate that the abnormal migration profile of mature human frataxin is directly linked to the acidic nature of its N-terminal a-helix.
Maturation of human frataxin is a two-step process
In order to better characterize the maturation process of human frataxin and to determine which of the previously reported sites are required for proper maturation, we generated mutants by site-directed mutagenesis on critical residues for the i-FXN, m 56 -FXN and m 81 -FXN cleavage sites (Fig. 1) . It was previously shown that the maturation of frataxin occurs in a two-step process mediated by MPP (34) . As MPP requires basic residues at position -2 or -3 from the cleavage site, we mutated to glycine the arginines at positions 53 and 54 (mut 53-54) or the Leu78 and the Arg79 (mut 78 -79) to avoid formation of m-FXN 56 -210 or m-FXN 81 -210 , respectively ( Fig. 1 ). To determine whether the maturation process necessitates the formation of the intermediate frataxin, the arginines at position 39 and 40 were mutated to glycine (mut [39] [40] . Finally, the different double and triple mutants were generated by combination of the above single mutations. 
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Each construct was transiently transfected in COS-1 cells and total extracts were analyzed by western blot (Fig. 5 ). The presence and the level of each form of frataxin in the different mutants are summarized in Table 1 .
The precursor, intermediate and mature forms of frataxin can easily be detected after overexpression of WT frataxin ( Fig. 5 and Table 1; 1) . Interestingly, the same profile is observed for mut 53-54 (Table 1; 1 and 3) , suggesting that the previously described site for m 56 -FXN is not the physiological relevant site for proper maturation of frataxin in vivo. Furthermore, the mut 78-79 mutation eliminates the presence of mature form (Table 1 ; 4), indicating that 78-79 residues are directly implicated in the final maturation step of frataxin at position 81 in agreement with the above mass spectrometry results. An alternative construct mutated at Arg79 and Lys80 also prevents the formation of mature frataxin (Supplementary Material, Fig. S2 ). Interestingly, for mut 78-79, there is an increase in the intermediate form as well as the presence of a strong band migrating faster than mature frataxin and close to the FXN 79 -210 (see below). Therefore, the maturation of frataxin occurs by a first cleavage of the precursor at residue 42, which gives rise to the i-FXN, followed by a second cleavage at amino acid 81, generating the m-FXN. From our mutational analysis, we can infer that the second cleavage requires the presence of Arg79, a highly conserved residue in mammalian frataxins.
The m 56 -FXN was never detected in endogenous conditions neither in cell cultures nor in tissues (data not shown). Interestingly, when the protein is mutated at residues 78-79, thereby impairing the normal maturation of frataxin, a band co-migrating with m 56 -FXN is detectable ( Fig. 5 The MALDI-PMF analysis of this 14-kDa product after Asp-N digestion of mut 53-54/78 -79 allows to detect a diagnostic peak corresponding to human frataxin 78-90 peptide (sequence¼GGKSGTLGHPGSL/D, data not shown). Despite the presence of glycine residues instead of leucine and arginine at positions 78 -79 of frataxin in the identified peptide, the co-migration of this d-FXN 14-kDa product in other mutants not mutated at residues 78 and 79 (i.e. mut [39] [40] indicates that m 78 -FXN can be produced in a cellular context. The presence of m 78 -FXN in the mut 39 -40 mutant (Table 1; (Table 1 ; 5) did not generate this increased level of mature form, further supporting the view that the formation of the mature protein is a two-step process. Altogether, these data confirm that mature frataxin is processed at amino acid 81, but also show that m 56 -FXN and m 78 -FXN can be produced in a cellular environment when the normal maturation process is impaired. Human
FACS (N. Carelle-Calmels, submitted for publication). With this system, we have shown that complete absence of frataxin in fibroblasts inhibits cell division and leads to cell death (N. Carelle-Calmels, submitted for publication). Furthermore, stable expression of a transgenic murine or human frataxin in these cells rescued the deleterious effect of the deletion of endogenous frataxin expression. We therefore used this new tool to determine the ability of the different frataxin forms to rescue the cell survival of cells deleted for endogenous frataxin. Fibroblasts expressing the conditional frataxin allele (Frda L3/L2 ) were stably transfected with different constructs containing either WT frataxin or the single or double maturation mutants (Fig. 6A) . After a second transient transfection with the fluorescent recombinase pEGFP-Cre, the cells were sorted by FACS and isolated one cell per well and cultured for 7 -10 days. As expected, no clones were able to grow when transfected with an empty vector (Fig. 6B) , confirming the lethality of total frataxin deficiency in these cells, while 30 clones with stable expression of WT frataxin were obtained (Fig. 6B) (Fig. 6B ). For each construct tested, the same number of EGFP-positive cells was isolated. The number of healthy clones was fewer with the mutant constructs than with WT frataxin suggesting that m 81 -FXN is more efficient and functional than m 56 -FXN and m 78 -FXN. However, the isolation of several clones with mutant constructs suggests that m 56 -FXN and m 78 -FXN could be functional to rescue cell survival, although we cannot exclude that the mutant constructs do not completely abolish the normal cleavage of the mature frataxin resulting in an undetectable pool of mature frataxin in these cells.
Maturation of frataxin occurs within the mitochondria in cells
The existence of an extramitochondrial pool of frataxin has recently been suggested by several groups (25, 38, 39) . In contrary, 
The number of þ indicates the relative increase of the corresponding form. NC means that the amount is identical to what is observed in non-transfected cells. 0 means the corresponding form is not observed. Table 1 for detailed analysis of the pattern). 
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we have recently shown in several mouse tissues that no cytosolic frataxin can be detected (6) . Furthermore, we detected mature frataxin exclusively in the mitochondrial matrix after subcellular fractionation experiments in HeLa cells (Fig. 7A) .
As a cytosolic form of m 56 -FXN was recently shown to be functional and able to rescue the survival of FRDA cells submitted to a stress (25), we hypothetized that the m 56 -FXN could possibly be processed outside the mitochondria. We thus performed subcellular fractionation on COS-1 cells transfected with the different frataxin mutant constructs. For each construct, again no forms of frataxin were detected in the cytosol [with the exception of the precursor (data not shown)] (Fig. 7B) , demonstrating that mature frataxin as well as m 56 -FXN are generated within mitochondria. These results further suggest that frataxin is exclusively a mitochondrial protein even under altered maturation conditions.
DISCUSSION
Frataxin is a nuclear-encoded protein, synthesized in the cytosol as a 210 amino acid precursor, which is targeted to the mitochondria and undergoes proteolytic processing to generate the functional mature form (m-FXN) (2, 33, 34, 40 form has been shown to be able to rescue frataxin-defective cells derived from FRDA patients from exogenous oxidative stress (25) . We therefore hypothesized that m 56 -FXN, as it is directly generated from the precursor, might be processed within the cytosol. However, our fractionation experiments clearly show that when the normal maturation process is impaired, m 56 -FXN is generated within the mitochondria, similar to the normal maturation process of WT frataxin. Although our experiments do not exclude the possibility that a cytosolic m 56 -FXN form could be processed under specific conditions endogenously, we have never detected the m 56 -FXN form in any tested cell lines and murine tissues. Human
Different groups have reported the existence of shorter forms of frataxin (d-FXN) occurring from 'spontaneous' proteolysis, with the major degradation form corresponding to m 78 -FXN (15, 23, 43) . In a recent report, the m 78 -FXN form was proposed to be generated by an iron-mediated self cleavage of the m 56 -FXN form (36) . The authors propose that this post-translational modification by autoproteolysis has a regulatory role, possibly in synchronizing iron influx into the matrix with delivery to target proteins, by generating the functional form of frataxin capable of iron delivering to IscU and ferrochelatase. On the other hand, another report suggests that dihydrolipoamide dehydrogenase (DLD) has a 'moonlighting' protease activity converting the m 56 -FXN form of frataxin to shorter forms of %14 kDa, the major one corresponding to m 77 -FXN (44) . As biochemical experiments have demonstrated that the d-FXN is unable to assemble and detoxify iron in vitro (43), the authors suggest that this cleavage by DLD is a mechanism to regulate the level of frataxin within the cell. Although our results do not directly address the proteolytic mechanism that leads to m 78 -FXN, it is clear that under our experimental conditions, the m 78 -FXN form can be generated either from the precursor, the intermediate form or the m 56 -FXN form when normal maturation is impaired, but not from the endogenous mature frataxin. Furthermore, although our functional test clearly shows that transgenic expression of a WT frataxin giving rise to the m 81 -FXN can rescue the cell death linked to endogenous frataxin deletion, m 56 -FXN and m 78 -FXN appear to also be functional, although less efficiently than m 81 -FXN. Particularly, m 78 -FXN appears to be far less efficient than m 81 -FXN and even m 56 -FXN. However, we cannot exclude that mutation of residues around each cleavage site do not completely abolish the normal cleavage, generating a small undetectable level of mature frataxin that can rescue endogenous frataxin deletion. Interestingly, the expression of a frataxin construct carrying mutation in residues 53-54 and 79-80, which therefore express only m 78 -FXN (this paper), failed to restore the aconitase activity deficiency in patients fibroblasts compared with WT frataxin or m 56 -FXN (35) .
Although the abnormal migration of frataxin has been recognized for a long time, our results show that only the mature m 81 -FXN presents this abnormal migration profile on SDS -PAGE. Indeed, different deletion constructs of FXN going from 56-210 to 79-210 migrate according to their theoretical molecular weights (Fig. 4) , while m 81 -FXN migrates in between the 71-210 and 64 -210 constructs. Furthermore, we show that depending on the acrylamide concentration, m 81 -FXN can co-migrate either with the m 78 -FXN or close to the m 56 -FXN. We exclude that this abnormal migration profile is due to a putative post-translational modification. The abnormal migration profile of frataxin has been attributed to the specific acidic nature of the protein due to the presence of a dozen acidic residues, involved in iron binding, localized at the surface of the protein. Mutations of some of these residues has been shown to modify the migration profile for yeast frataxin (31, 37) , potentially through a change in the electrostatic potential of the protein.
In agreement, we demonstrate that point mutations in some N-terminal acidic residues of human frataxin can change its migration in gel, notably to a migration according to its calculated molecular weight. It is interesting to note that two independent reports suggest that the N-terminal residues (residues 75-90), which has a 3 10 -helix, lies toward the a1-helix and the b1-sheet of the core structure of frataxin (residues 91-210) (16) , and may through multiple electrostatic contacts block access to the anionic surface. The property of such secondary structure of the N-terminus of frataxin might be responsible for the abnormal migration profile. It is tempting to speculate, based on our results as well as published results (17, 37) , that acidic residues are important for the proper folding of the N-terminus of m 81 -FXN, while the presence of residues L78, R79 and K80, not normally present in the mature FXN, might prevent it.
In conclusion, we have shown that the major endogenous form of mature human frataxin is m 81 -FXN, in agreement with one of the recently reported mature forms of frataxin (35) . Furthermore, we show that m 81 -FXN is fully functional for cell survival, and that the two-step maturation process occurs entirely within the mitochondria. Both crystallographic data and solution NMR structures suggest that the core of frataxin (residues 90 -210) is rigid (28, 29) . The identification of the final maturation step at amino acid 81 indicates that this core structure covers most of the mature frataxin, and that the resulting size of m 81 -FXN (130 amino acids), is very comparable in size with the mature yeast and bacterial protein. Recently, in yeast, the N-terminal part of the mature protein which has a 3 10 helix was suggested to stabilize a trimer conformation (45) , suggested to be the functional unit of frataxin giving iron to its partners and the building blocks for frataxin oligomerization for iron storage and iron detoxification (46) . Although the m 78 -FXN form has been shown to be unable to oligomerize (47) , it will be of interest to determine whether the m 81 -FXN is capable of forming trimers and oligomers. In the future, the clear determination of the structure and biochemical properties of the mature human m 81 -FXN is important not only to determine the in vivo role of human frataxin in Fe -S and heme biosynthesis as well as in iron storage and detoxification, but also as it will provide essential tools and knowledge to envisage new therapeutical approaches for FRDA based on protein stabilization or replacement therapies.
MATERIALS AND METHODS
Plasmids constructions and mutagenesis
Mutations in frataxin were introduced by primer-directed PCR mutagenesis (Supplementary Material, Table S1) using 10 ng of pcDNA3.1-hFXN vector, which contains human frataxin cDNA and Pfu DNA polymerase (10 U) in the presence of 2 ng/ml of primers, 200 mM of dNTP. Each mutation corresponds to the replacement of the indicated residue by glycine. Frataxin N-terminal truncated mutants were amplified from pcDNA3.1-hFXN by classical PCR (Supplementary Material, Table S1 ) and cloned using EcoRI/XhoI restriction sites into a pENTR1A Gateway entry vector (Invitrogen) and recombined in a pSG5 vector using the GATEWAY technology (Invitrogen) according to the manufacturer's protocol.
All constructs were verified by sequencing. Genotyping was performed as previously described (7).
Total protein extraction and subcellular fractionation
Cells were washed twice with PBS and then scrapped in TrisHCl 100 mM, pH 7.5, 10% glycerol, complete protease inhibitor cocktail (Roche) (Buffer A). Total extracts were obtained by re-suspending cells in the same buffer supplemented with 0.2% Triton X-100 and incubating on ice for 30 min. Suspensions were centrifuged 10 000g, 10 min, 48C and the protein concentration of supernatants was determined using Bradford reagent. For the subcellular fractionation, cells were washed twice with PBS and then scrapped in Buffer A. The cell pellet was washed once with the same buffer before adding 0.014% digitonin for 10 min at 48C. The suspension was centrifuged at 10 000 g, 48C for 10 min. The supernatant was further centrifuged at 25 000g, 48C for 30 min to get the soluble cytosolic fraction, while the pellet, corresponding to the enriched mitochondrial fraction, was re-suspended in buffer A using a 25-G syringe and centrifuge at 500g, 48C for 5 min to eliminate membranes and nuclear fraction. The mitochondrial fraction was obtained by centrifugation at 10 000g, 48C for 10 min and washed twice with buffer A. The mitochondrial pellet was re-suspended in buffer A containing 0.2% Triton X-100 and incubated for 30 min at 48C to get, after centrifugation, mitochondrial extracts.
Western blotting and in vitro transcription/translation assay
Two different protein electrophoresis systems were used (SDS -Glycine -PAGE with 12, 13, 14 or 15% acrylamide and SDS-Tricine -PAGE 16%) and western blot were carried out as previously described (7) . Note that we used 14% acrylamide SDS-Glycine -PAGE, when it is not precise. Antibodies were diluted as follow: anti-frataxin 1/1000 (R1270, directed against peptide TLDNPSSLDE-TAYERLAEETL) (7) or monoclonal 1G2 (Mitoscience)); anti-b-tubulin 1/5000 (MAB3408, Chemicon International); anti-MnSOD 1/5000 (SOD-110, StressGen). HRP-coupled secondary antibodies were diluted at 1/5000. In vitro transcription/ translation of recombinant frataxin protein was produced according to the manufacturer's protocol (Promega) using the TnTw quick-coupled transcription/translation systems and then analyzed by western blot.
Immunopurification and staining of mature frataxin
The immunoprecipitating monoclonal 1G2 frataxin antibody was cross-linked to G-sepharose beads using dimethyl pimelimidate (DMP, Sigma). Briefly, antibody was incubated with the beads and then washed twice with borate buffer 0.15 M, pH 9.0. Beads were incubated twice with 20 mM DMP for 30 min. Cross-linking reaction was stopped by 2 h incubation in ethanolamine 0.2 M, pH 8.0. Beads were washed once with glycine 1 M, pH 2.5, to eliminate uncross-linked antibody and twice with PBS to eliminate glycine.
Total cell extracts were prepared from Hela cells transiently transfected with WT frataxin. Immunoprecipitation was carried out in Tris-HCl 100 mM, pH 7.5, 0.1% NP40 containing protease inhibitors (Roche) using 1 mg of total proteins and the cross-linked 1G2 antibody, overnight at 48C.
Beads were pelleted by centrifugation at 5000g, 5 min, 48C and washed four times with Tris -HCl 100 mM, pH 7.5, containing 250 mM NaCl, 0.1% NP40 and protease inhibitors. Two washes were done without any salt. Beads were resuspended in glycine 1 M, pH 2.5, to elute immunoprecipitated frataxin and prevent contamination by the cross-linked antibody. pH of the sample was neutralized by adding a small volume of Tris 1 Mbuffer, pH 8.8. Several immunoprecipitation were pooled together and concentrated in a small volume with the Vivaspin system (Vivascience). Loading buffer was added and samples were boiled 10 min before analysis on 14% SDS -Tris-Glycine -PAGE. Immunoprecipitated frataxin was detected by classical silver nitrate staining (48) . Slices from silver nitrate stained gel were excised and subjected to MALDI-TOF spectrometry analysis.
Mass spectrometry analyses
In gel digestion. Enzymatic digestion of excised bands was performed as previously described (49) . Depending on the gel volume, 5 -10 ml of 10 ng/ml Porcine Trypsin (V511A, Promega) or of 10 ng/ml Pseudomonas fragi Asp-N (Roche) were added. Each enzyme was freshly diluted in 25 mM NH 4 HCO 3 . The digestion was performed overnight at room temperature (RT). Five mircoliters of 40% H 2 O/60% acetonitrile/0.1% TFA were added, and samples were incubated for 3 h at RT. After 2 min sonication, 0.5 ml of peptide extracts was used for MALDI analyses.
Human Molecular
MALDI measurements. Peptide extracts (0.5 ml) were mixed with an equal volume of 2,5-dihydroxybenzoic acid (DHB, 10 mg/ml) purchased from Sigma (Sigma-Aldrich). DHB was dissolved in 20% acetonitrile and crystals were obtained using the dried droplet method. MALDI MS measurements were carried out on a Bruker Reflex IV MALDI-TOF spectrometer, at a maximum accelerating potential of 20 kV and in positive reflectron mode. The acquisition range was set to m/z 800 -3000 with low mass gate at m/z 700. Approximately 300 mass spectra were averaged per spot to optimize the signal-to-noise ratio. Monoisotopic peptide masses were assigned using the FlexAnalysis software (Bruker Daltonics). For positive mode measurements after enzymatic digestions, internal calibrations were performed using peaks corresponding to autolytic peptides of the enzymes: m/z ¼ 842.509 and 2211.104 for trypsin; m/z ¼ 1022.521, 1365.622, 1917.062 for Asp-N.
Tools for interpretation of MALDI-PMF data
Peak lists from recombinant proteins were submitted to the FindMod and FindPep software (http://www.expasy.org/ tools) using the following parameters: enzymatic digestion trypsin (cleavage at the C-terminus of Arg and Lys residues even before Pro) or Asp-N (cleavage at the N-terminus of Asp and Glu residues); iodoacetamide treatment on cysteines was considered complete and methionine oxidation only partial; tolerance 50 ppm. Sequence coverage percentages have been manually calculated. The submitted sequence for the analyses was human frataxin (Q16595). 
